12:00 AM
 | 
Mar 31, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coveragec Opinion Wk chg 3/28 cls
Antares (AMEX:AIS) Punk Mathew Kaplan Price target Buy 4% $0.95
Kaplan lowered his target to $2 from $3. He expects the potential launch of the needle-free device for a human growth hormone from partner Teva (NASDAQ:TEVA) will be delayed until February 2009 from 2H08.
Auxilium (NASDAQ:AUXL) Merriman Curhan Ford E. Russell McAllister Downgrade Sell (from neutral) 14% $26.27
McAllister believes there were a number of unexpected adverse events in the Phase III CORD I and CORD II trials that will delay the approval and launch of Xiaflex (AA4500), an injectable form of collagenase ABC enzyme to treat Dupuytren's disease. The company expects to have data in 2Q08.
Avant (NASDAQ:AVAND) Needham Alan Carr Upgrade Buy (from hold) 34% $9.61
Carr upgraded and set a $10 target after Avant completed its merger with Celldex (see BioCentury, March 17). He believes there is synergy between the two platforms and noted a stronger, more diverse pipeline. He expects increased news flow, including an April 3 PDUFA date for a BLA for Rotarix oral attenuated rotavirus vaccine, which is partnered with GlaxoSmithKline (LSE:GSK; NYSE:GSK), and Phase II data next quarter for Ty800 to prevent typhoid.
Endo (NASDAQ:ENDP) Susquehanna Angela Larson Upgrade Net positive (from neutral) 2% $23.70
Larson lowered her...

Read the full 1279 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >